Skip to main content

FDA Approvals

FDA Approvals
Trodelvy (Sacituzumab Govitecan-hziy) a New Targeted Therapy for Patients with Metastatic Triple-Negative Breast Cancer
Loretta Fala
Read More
FDA Approvals
Zejula (Niraparib) First PARP Inhibitor Approved for First-Line Maintenance Therapy in All Women with Advanced Ovarian Cancer, Regardless of Biomarker Status
Loretta Fala
Read More
FDA Approvals
FDA Approvals of Brand-Name Prescription Drugs, January 1, 2019, Through June 15, 2020
Read More
FDA Approvals
FDA News: August 2020
Read More
FDA Approvals
Tumor-Infiltrating Lymphocyte Therapy Induces Responses Across Wide Range of Patients with Advanced Melanoma
Wayne Kuznar
Wayne Kuznar
Read More
FDA Approvals
The WEE1 Inhibitor Adavosertib Displays Promising Clinical Activity in Uterine Serous Cancer
Wayne Kuznar
Wayne Kuznar
Read More
FDA Approvals
Intratumoral Injection of Cisplatin and Vinblastine, with or without Pembrolizumab, Improves Intracellular Transport in Patients with Advanced Solid Tumors
Chase Doyle
Chase Doyle
Read More
FDA Approvals
Opdivo Approved for Advanced Esophageal Squamous-Cell Carcinoma
Read More
FDA Approvals, Lung Cancer, Oncology
FDA Approves Cyramza plus Tarceva for First-Line Treatment of Metastatic NSCLC with EGFR Mutation
Read More
FDA Approvals, Lung Cancer, Oncology
Opdivo plus Yervoy and Limited Chemotherapy Approved as First-Line Therapy for Metastatic NSCLC, Regardless of PD-L1 Expression
Read More
Page 16 of 53
Results 151 - 160 of 524